| abstract |
Described herein are intratumoral and interstitial nanomaterials that can be used to identify imaging signatures to predict cancers (eg, in low-grade and/or high-grade brain cancers (eg, in gliomas, such as primary gliomas)) Particle-driven radiogenomics systems and methods for particle distribution. In certain embodiments, the systems and methods described herein extract and combine quantitative multidimensional data generated from structural, functional and/or metabolic imaging. In certain embodiments, the combined multidimensional data is related to intratumoral and interstitial nanoparticle distribution. For example, this correlation data can be used to determine quantitative functional-metabolic multimodal particle-based imaging signatures and predict therapeutic efficacy. Compared to traditional size-based imaging methods, these techniques offer improved quantitative capabilities to measure treatment response and determine tumor progression. |